Company: ImStar Therapeutics
Drug Type: Protein Biologic
Mechanism Type: Immunomodulation
Mechanism: TDP-43 abnormally accumulates aggregates in the cytoplasm of the vast majority of ALS patients. In addition, recent studies have shown that TDP-43 activates NFkB, and may increase inflammation via this pathway. This approach, known as TDP-43-associated nuclear factor-kB (NFkB) activation (TANA) inhibitors, aims to reduce neuroinflammation by targeting this pathway.
U.S. Status for ALS: Preclinical
 ImStar Therapeutics. Pipeline. ImStar Therapeutics, n.d. Pipeline. Accessed 9 Mar 2016 from http://imstartx.com/pipeline.html.
 Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB-mediated pathogenic pathways. Swarup, V et al. J Exp Med. 2011 No 21;208(12):2429-47.
Last updated February 14th, 2018